

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen” or “the Company”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

CAUTIONARY ANNOUNCEMENT – DISCUSSIONS TO CONCLUDE COVID-19 LICENSING AGREEMENT

Shareholders are advised that Aspen are in advanced discussions in relation to the possible conclusion of a licensing agreement to allow it to produce and sell a Covid-19 vaccine in Africa. Aspen currently produces vaccines under contract on a ‘fill and finish’ basis.

The successful conclusion of this licensing agreement may have a material effect on the price of Aspen's securities and, accordingly, shareholders are advised to exercise caution when dealing in the Company's securities.

Durban
29 November 2021

Sponsor
Investec Bank Limited